Current Feed Content from 13 Aug 08 11:54
New Drug Monograph for Pentacel
Wed, 06 Aug 2008 08:00:00 GMTThe FDA has approved Pentacel (diphtheria/tetanus toxoids and acellular pertussis/poliovirus, inactivated/Haemophilus b vaccine) for immunization against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b for children 6 weeks through 4 years of age. Learn more at www.epocrates.comNew Monograph for Kinrix
Wed, 30 Jul 2008 08:00:00 GMTThe FDA has approved Kinrix (diphtheria/tetanus toxoids and acellular pertussis/poliovirus, inactivated vaccine) for combination immunization in children 4-6 years old. Learn more at www.epocrates.comNew Monograph for zaleplon
Wed, 23 Jul 2008 08:00:00 GMTFirst-time generic formulations for zaleplon are now available. Zaleplon is equivalent to Sonata, which is indicated for the short-term treatment of insomnia (sleep-onset type). Learn more at www.epocrates.comNew Monograph for Risperidone
Wed, 16 Jul 2008 08:00:00 GMTThe FDA has approved first-time generic formulations for risperidone. Risperidone is equivalent to Risperdal, which is indicated for the treatment of schizophrenia and the acute mania of bipolar disorder in adults and children. It is also approved for irritability symptoms in children with autistic disorder. Learn more at www.epocrates.comNew Monthly Dosing for Actonel
Wed, 09 Jul 2008 08:00:00 GMTThe FDA has approved once-monthly dosing of Actonel (risedronate) for the prevention and treatment of postmenopausal osteoporosis. Learn more at www.epocrates.comNew Black Box Warning for Conventional Antipsychotics
Wed, 02 Jul 2008 08:00:00 GMTThe FDA has reviewed data indicating that conventional antipsychotics are also associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. In 2005, the same black box warning was added to the atypical antipsychotics. Neither conventional nor atypical antipsychotics are approved for dementia-related psychosis. Learn more at www.epocrates.comExpanded Indication for Advair Diskus
Wed, 25 Jun 2008 08:00:00 GMTThe FDA has approved Advair Diskus (fluticasone/salmeterol inhaled) for maintenance therapy of COPD, which now includes the treatment of emphysema as well as chronic bronchitis. Learn more at www.epocrates.comNew Black Box Warning for Regranex
Wed, 18 Jun 2008 08:00:00 GMTThe prescribing information for Regranex (becaplermin topical) now includes a black box warning. An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of Regranex in a post-marketing retrospective cohort study. Regranex should only be used when the benefits can be expected to outweigh the risks. Use with caution in patients with known malignancy. Learn more at www.epocrates.comNew Drug Monograph for Relistor
Wed, 11 Jun 2008 08:00:00 GMTThe FDA has approved Relistor (methylnaltrexone) to treat opioid-induced constipation. Learn more at www.epocrates.comAdditional Indication for Amitiza
Wed, 04 Jun 2008 08:00:00 GMTThe FDA has approved Amitiza (lubiprostone) to treat irritable bowel syndrome with constipation in women, making it the first drug to win approval for this condition. Learn more at www.epocrates.comNew Dosage Form for Paroxetine
Wed, 28 May 2008 08:00:00 GMTThe FDA has approved a first-time generic extended-release form of paroxetine. Paroxetine ER is equivalent to Paxil CR, which is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysmorphic disorder. Learn more at www.epocrates.comNew Drug Monograph for Ropinirole
Wed, 21 May 2008 08:00:00 GMTThe FDA has approved first-time generic formulations for ropinirole. Ropinirole is equivalent to Requip, which is indicated for the treatment of moderate to severe primary restless legs syndrome and for Parkinson's disease. Learn more at www.epocrates.comAdult Indication and Additional Capsule Sizes for Vyvanse
Wed, 14 May 2008 08:00:00 GMTThe FDA has approved Vyvanse (lisdexamfetamine) for the treatment of ADHD in adults. It is also now available in 20 mg, 40 mg, and 60 mg capsule strengths. Learn more at www.epocrates.comNew Drug Monograph for Pristiq
Wed, 07 May 2008 08:00:00 GMTThe FDA has approved Pristiq (desvenlafaxine), the major active metabolite of venlafaxine, for the treatment of major depressive disorder in adults. Learn more at www.epocrates.comNew Drug Monograph for Fenoglide
Wed, 30 Apr 2008 08:00:00 GMTThe FDA has approved Fenoglide (fenofibrate) for the treatment of hyperlipidemia, mixed dyslipidemia, or hypertriglyceridemia. Learn more at www.epocrates.comPediatric Indication for Reyataz
Wed, 23 Apr 2008 08:00:00 GMTThe FDA has approved Reyataz (atazanavir) for the treatment of HIV infection in patients 6-17 years of age. Learn more at www.epocrates.comAdditional Indication for Aloxi
Wed, 16 Apr 2008 08:00:00 GMTThe FDA has approved Aloxi (palonosetron) for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Learn more at www.epocrates.comNew Drug Monograph for Renvela
Wed, 09 Apr 2008 08:00:00 GMTThe FDA has approved Renvela (sevelamer) for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Learn more at www.epocrates.comNew Drug Monograph for Treanda
Wed, 02 Apr 2008 08:00:00 GMTThe FDA has approved Treanda (bendamustine) for the treatment of chronic lymphocytic leukemia (CLL) in adult patients. Learn more at www.epocrates.comNew Dosage Forms for OxyContin
Wed, 26 Mar 2008 08:00:00 GMTOxyContin is now available in an expanded array of tablet strengths. The new extended-release tablets are 15 mg, 30 mg, and 60 mg. The 60 mg tablets are only to be used in opioid-tolerant patients. Learn more at www.epocrates.com
Have the latest drug information at your fingertips with Epocrates mobile and online drug databases. Epocrates drug information is trusted by more than 500, 000 healthcare professionals to be objective, accurate, current, concise, and clinically relevant. Learn more at www.epocrates.com
feedcat.net promotes your content, measures audiences
and saving load of your server resources!
*